Compare CHGG & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | STTK |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 119.0M |
| IPO Year | 2013 | 2020 |
| Metric | CHGG | STTK |
|---|---|---|
| Price | $0.88 | $3.09 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $1.42 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.8M | 328.1K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,733,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $0.69 |
| 52 Week High | $2.40 | $3.38 |
| Indicator | CHGG | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 68.57 |
| Support Level | $0.83 | $1.93 |
| Resistance Level | $1.03 | $3.30 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.50 | 77.24 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.